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Background: Global ambitions to eliminate malaria are intensifying, underscoring a critical need for transmission
blocking tools. In 2012, the WHO recommended the use of 0.25 mg/kg of single low-dose (SLD) primaquine to stop
Plasmodium falciparum transmission. To ensure the availability of SLD primaquine to countries in need of this tool,
more information on the supply, programmatic, and regulatory barriers to the rollout of SLD primaquine is required.
Methods: Challenges to the rollout of SLD primaquine in sub-Saharan Africa were established through semi-structured
qualitative interviews with three primaquine manufacturers, 43 key informants from Ethiopia, Senegal, Swaziland,
Zambia, and Tanzania, and 16 malaria research experts.
Results: Sanofi and Remedica are the only two sources of SRA-approved primaquine suitable for procurement by
international donors. Neither manufacturer produces primaquine tablet strengths suitable for the transmission blocking
indication.
In-country key informants revealed that the WHO weight-based recommendation to use SLD primaquine is
challenging to implement in actual field settings. Malaria programmes expressed safety concerns of SLD primaquine
use in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, as well as potential interactions
between primaquine and co-morbidities, and drug-drug interactions with HIV and/or tuberculosis treatments.
Regulatory processes are a major barrier to the rollout of SLD primaquine, requiring multiple steps at both the country
and global level. Despite these barriers, demand for SLD primaquine is growing, and malaria researchers are interested
in primaquine deployment through mass screen and treat and/or mass drug administration campaigns.
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Conclusion: Demand for primaquine as a transmission blocking agent is growing rapidly yet multiple barriers to SLD
primaquine use exist. Research is needed to define the therapeutic dose range, which will guide dosing regimens in
the field, inform the development of new, lower strength primaquine tablets and/or formulation(s), and allay
programmatic safety concerns in individuals with G6PD deficiency. Potential interactions between primaquine
and co-morbidities and treatments should be explored. To minimize regulatory delays, countries need to prepare
for product registration at an early stage, WHO prequalification for suitable primaquine tablet strengths and/or
new formulations should be sought, and in the meanwhile only Stringent Regulatory Authority (SRA)-approved
primaquine should be used.
Keywords: Primaquine, 8-aminoquinoline, Plasmodium falciparum, Africa, Glucose-6-phosphate dehydrogenase
deficiency, G6PD, Drug dosing, Drug production, Drug manufacturing, Drug regulation, Malaria transmissionBackground
Over the past 13 years, the success of malaria control
programmes have contributed to a decrease in malaria
mortality rates by approximately 50% worldwide [1]. To
maintain these gains, the World Health Organization
(WHO) recommends use of the drug primaquine, in
conjunction with an artemisinin-based combination
therapy (ACT), to block Plasmodium falciparum trans-
mission in areas approaching malaria elimination and/or
facing artemisinin resistance [2].
Primaquine is an old drug that has been on the market
for over 60 years [3]. Originally developed as a 14-day
course of treatment for the radical cure of Plasmodium
vivax malaria, there is now growing interest in a second
indication for primaquine, as a single low dose, to clear
mature, late-stage P. falciparum gametocytes. As prima-
quine is the only commonly used anti-malarial on the
market that kills mature gametocytes, the malaria life
cycle stage responsible for the transmission of malaria
from the human to the mosquito, its use for this second
indication is expected to accelerate efforts to eliminate
P. falciparum malaria [4].
The use of primaquine is often hampered by safety
concerns, as it is known to cause dose-dependent haem-
olysis in individuals deficient in glucose-6-phosphate de-
hydrogenase (G6PD), an enzyme involved in the pentose
phosphate pathway [5]. Haemolytic side-effects depend
mostly on the dose of primaquine used and the host
variant of G6PD deficiency, and can range anywhere
from asymptomatic haemolysis to acute haemolytic an-
aemia, and in rare cases, renal failure and death [5].
While the 14-day course of primaquine (0.25–0.5 mg/kg
per day for 14 days) treatment required for the radical
cure of P. vivax malaria is considered to be unsafe for
G6PD-deficient (G6PDd) individuals, the WHO con-
siders a single low dose (0.25 mg/kg) of primaquine to
be safe for individuals with G6PD-deficiency, as impliedby their recommendation to use primaquine as a P. fal-
ciparum gametocytocide [6].
The WHO recommendation for single low-dose (SLD)
primaquine use was issued in October 2012, and does
not come with the statement “Strong recommendation,
high quality evidence” that typically accompanies WHO
recommendations for anti-malarial use [6]. The recom-
mendation was based on a pooled analysis of unstan-
dardized infectivity studies, and the dose was lowered
from the previously recommended 0.75 mg/kg dose, ex-
cluding G6PDd individuals, uptake of which was limited
due to safety concerns and a lack of infrastructure for
G6PD testing [2]. Since 2012, three countries in the
Greater Mekong Subregion have adopted SLD prima-
quine as policy, and seven countries in sub-Saharan
Africa have written SLD primaquine into policy docu-
ments, although the actual level of implementation and
adherence to these policies is unclear [7].
Since SLD primaquine is recommended by the WHO
and is being written into country policies, its use as a P.
falciparum gametocytocide is expected to grow. How-
ever, the global production and supply of primaquine are
still tailored for its use for P. vivax malaria, at different
dose regimens, and hence with a different safety profile
for G6PDd individuals. The label for primaquine lists its
indication for the radical cure of P. vivax malaria only;
dose instructions are for P. vivax malaria, and the use of
primaquine for P. falciparum remains off-label. As the
use of SLD primaquine for P. falciparum malaria grows,
changes in the global demand for primaquine are ex-
pected and changes in the global supply will thus be
required.
This study was conducted to identify supply, program-
matic, and regulatory barriers to the rollout of SLD
primaquine for P. falciparum elimination in sub-Saharan
Africa, where P. falciparum comprises the vast majority
of malaria infections. The study was a research priority
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of stakeholders in 2012 to facilitate the deployment of
SLD primaquine in sub-Saharan Africa [8]. This paper is
a summary of the key findings from a full report that
can be found elsewhere [9].Methods
Manufacturers
In order to explore the production landscape of prima-
quine and market demand for SLD primaquine, select
manufacturers of primaquine were interviewed (inter-
view guide in Additional file 1). Manufacturers of prima-
quine were identified through a review of procurement
databases, life sciences analyst reports, drug regulatory
agency databases, drug company websites, and scientific
and public health reports. From a total of 51 manufac-
turers of primaquine identified, two manufacturers that
produce Stringent Regulatory Authority (SRA)-approved
primaquine, Sanofi and Remedica, and the main manu-
facturer of the active pharmaceutical ingredient (API) of
primaquine, Ipca, were selected for interview. Sanofi and
Remedica, the only producers of SRA-approved prima-
quine, were interviewed because international donors,
such as the Global Fund to fight AIDS, Tuberculosis and
Malaria (GFATM), require that either SRA approval or
WHO prequalification be obtained for all drugs to be
procured through their funding mechanism, and there is
no WHO prequalified primaquine product.
As defined by the WHO, a SRA is a regulatory authority
which is: (a) a member of the International Conference on
Harmonization (ICH); or (b) an ICH Observer, being the
European Free Trade Association (EFTA), as represented
by Swissmedic and Health Canada; or (c) a regulatory au-
thority associated with an ICH member through a legally-
binding mutual recognition agreement including Australia,
Iceland, Liechtenstein and Norway [10].
Ipca was identified through its FDA Drug Master File
(DMF) and interviewed as the main manufacturer of
primaquine API, the critical component which other
pharmaceutical companies use to manufacture prima-
quine tablets (according to the FDA DMF [11]). A DMF
is a submission of required information to the FDA that
permits the FDA to confidentially review informationTable 1 Number of key informant interviews conducted by country
Country NMCP Drug Regulatory Authority Ke
Swaziland 4 0 0
Zambia 1 1 1
Senegal 4 3 3
Ethiopia 1 2 1
Zanzibar 4 3 0
TOTAL 14 9 4about facilities, processes, or articles used in the manu-
facturing, processing, packing and storage of drugs [11].
In-country perspectives
To assess demand and understand in-country concerns
around SLD primaquine use, five countries in sub-Saharan
Africa were chosen as case studies: Ethiopia, Senegal,
Swaziland, Zambia, and Tanzania (Zanzibar). These coun-
tries were selected based on their expressed interest in
using SLD primaquine, their goals of national or sub-na-
tional malaria elimination, their geographic diversity
within Africa, and their varying population sizes. Key in-
formants were purposefully selected for interview to rep-
resent the views of a range of levels and roles within the
health system. A total of 43 in-country key informants
were interviewed (Table 1, interview guide in Additional
file 1), including but not limited to: 1) members of the Na-
tional Malaria Control Programme (NMCP); 2) the local
equivalent of a Drug Regulatory Authority; 3) key end
users or implementers such as clinicians and professors
with malaria expertise; and 4) in-country malaria partners
(e.g., WHO, UNICEF, President’s Malaria Initiative). Add-
itionally, 16 semi-structured interviews were conducted
with global key informants with no specific country affili-
ation (interview guide in Additional file 1). Global key in-
formants were comprised of academic malariologists, as
well as organizations implementing research projects
using SLD primaquine across multiple countries (Table 1).
All individuals chosen for interviews were selected based
on their professional affiliation, as well as relevant experi-
ence and knowledge in malaria.
Data collection
Interviews with select manufacturers and key informants
in sub-Saharan Africa were conducted from April to
July, 2013 by one of the investigators (MN) to ensure
consistency across interviews. Interviews followed a
semi-structured interview guide and were conducted by
phone, email, or during scheduled in-country meetings.
Interviews with manufacturers explored the production
landscape of primaquine and market demand for SLD
primaquine. These interviews revealed a need to de-
velop a lower strength tablet of primaquine, after which
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high quality, SRA-approved products, including various
drug formulations. This second interview with Sanofi
focused on establishing the process required to develop
new tablets and/or paediatric formulations, and gauging
manufacturer interest in undertaking these processes.
The key informant interviews with in-country infor-
mants explored in-country perspectives of SLD prima-
quine use, including barriers to uptake, deployment
options, and the feasibility of overcoming the barriers
identified. Key informant interviews with global malaria
researchers/implementers were focused on primaquine
implementation, including supply, context for use, de-
ployment options, and the feasibility of overcoming
barriers to delivery. The majority of interviews were
conducted in English with the exception of Senegal
where, when necessary, the assistance of a French
translator was requested to facilitate discussions. All
interview questions were open ended, and handwritten
or electronic notes were collected by the moderator
(MN) during interviews.
Analyses
Thematic analysis, a method that applies inductive reason-
ing by which themes emerge from the data through careful
examination [12] was performed after familiarization of
the data. The first level of analysis was conducted by an in-
vestigator (MN) who reviewed and analysed all docu-
ments, meetings, interviews, and email correspondences.
A second level of analysis was performed by another inves-
tigator (RS). Together, MN and RS identified key themes
based on frequency of appearance and contextual import-
ance centered on the available literature, the primary re-
search question, and consultation with topic experts.
Emergent themes from interviews were discussed and
compared regularly among authors (MN, LR, RG, and JH)
to identify core consistencies across interviews and themes
were collated to provide a view of barriers to SLD prima-
quine rollout and use. Recommendations were then syn-
thesized for the barriers identified.
Results
Primaquine supply
Of the 51 manufacturers of primaquine identified, most
were located in Asia. Sanofi and Remedica were the only
producers of SRA-approved primaquine, and Ipca was
identified as the main manufacturer of primaquine API.
A few manufacturers of non SRA-approved primaquine
were also interviewed.
Sanofi’s current primary customer is the United States
Army, which places a single order of primaquine, usually
on a yearly basis. Sanofi primaquine remains relatively
expensive, with a current selling price of approximately
$0.50 per 15 mg tablet as compared to Remedica tablets,which are approximately $0.03 per 7.5 mg tablet [9]. The
high price is driven primarily by low demand and high
quality of FDA-approved API. Sanofi FDA-approved
primaquine is currently manufactured in Canada. A
Sanofi plant in Colombia, GMP-certified by Colombian
and Argentinean regulatory authorities, also produces
15 mg primaquine tablets, for regional markets, with
greater capacity. Sanofi is working on optimizing pro-
duction costs at both plants, and exploring various
scenarios to register primaquine in malaria-endemic
countries in which P. falciparum elimination could be
considered.
Remedica tablets are SRA-approved by the Cyprus
Ministry of Health-pharmaceutical services, a National
competent authority listed by the SRA European Medi-
cines Agency (EMA). Since 2011, Remedica has been the
primary supplier of primaquine purchased through the
GFATM, of which procurement has been growing rap-
idly over the past few years. In 2012, Remedica supplied
approximately 34 million primaquine tablets to the
GFATM [9], mostly for the radical cure of P. vivax mal-
aria in southern and Southeast Asia. As SRA approval is
often the minimum requirement for countries to pro-
cure drugs with international donor funding, Remedica
supplies primaquine directly to countries, and also
through donors, including UNICEF and the WHO/Roll
Back Malaria Partnership.
Ipca is a major pharmaceutical manufacturer in India,
producing approximately 2.4 million kg of assorted APIs
per year, including approximately 48,000 kg of prima-
quine annually in two batches. Prices of primaquine
phosphate API have increased over the past few years
but this may change soon, as the US-based company
Apicore LLC received an FDA Drug Master File for
primaquine in July 2013, bringing more competition to
the market.
Manufacturers that produce non SRA-approved
primaquine stated a number of reasons for not seeking
SRA approval for this drug. The most common reason
was uncertainty around the commercial demand of an
SRA-approved primaquine tablet. However, when told
about growing interests in using SLD primaquine as a
gametocytocide in African countries, manufacturers
generally expressed an interest in developing a higher
quality primaquine product and potentially seeking
SRA approval or WHO prequalification. WHO pre-
qualification is of particular interest for SLD prima-
quine, as most anti-malarials to date, including ACT,
have undergone this route for use in sub-Saharan Af-
rica. However, it is currently not possible for SLD
primaquine to proceed through WHO prequalifica-
tion, as SLD primaquine would first need to be listed
on the WHO prequalification programme Expression
of Interest (EOI) list, after which the WHO prequalification
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primaquine.Dosing
In-country interviews with key end users revealed that a
major barrier to primaquine uptake is the lack of clarity
of primaquine dosing in clinical settings. The current
WHO recommendation is a weight-based 0.25 mg/kg
dose, which is challenging to implement in actual field
settings, where dosing is usually based on patient age.
Age-based dosing bands are derived from the thera-
peutic dose range, a weight-based range spanning from
the lowest efficacious dose to the highest safe dose,
translated using weight-for-age data [13]. As primaquine
safety depends on dose, there is a critical need to inform
dosing practices by defining the therapeutic dose range
of SLD primaquine for P. falciparum gametocytes.
The width of the therapeutic dose range of primaquine
also has implications for dosing practices in clinical set-
tings. Figure 1 illustrates several hypothetical therapeutic
dose ranges of primaquine, and how these ranges may
affect dosing practices, per the WHO recommendation.
For example, if a 10 kg and a 20 kg child are dosed, and
the therapeutic dose range is defined as 0.12 to 0.3 mg/kg,
both children could be treated with a single 3 mg tablet of
primaquine. However, if the therapeutic dose range were
narrower, the dosing regimen becomes more complicated;
the 10 kg child would require one 2.5 mg tablet while the
20 kg child would need two 2.5 mg tablets. Tablet strength
becomes important, as bigger strengths may not afford
weight-based coverage for paediatric patients, as highlighted
in red (Fig. 1).Fig. 1 The effects of hypothetical primaquine therapeutic dose ranges onAs the WHO recommends that SLD primaquine be
used with an ACT, the dosing bands for commonly used
types of ACT are also shown in Fig. 1. Dosing practices
would be easier if the dosing bands for ACT and prima-
quine could be aligned, but this will unfortunately be chal-
lenging, as the dosing bands for artesunate-amodiaquine
(AS-AQ) differ significantly from those for artemether–
lumefantrine (AL) and dihydroartemisinin–piperaquine
(DHA–PPQ).
To enable the use of SLD primaquine across the
paediatric population, researchers and manufacturers
agreed on a need for the development of a lower strength
tablet for SRA approval or WHO prequalification. The
current SRA-approved tablets, available from Remedica
and Sanofi, are only available in 7.5 or 15 mg strengths, re-
spectively, which do not allow for accurate dosing in sub-
sections of the paediatric population. Although generic
companies in India produce primaquine tablets at 2.5 mg
strength, these are not SRA-approved and therefore do
not meet the quality standards set out by international do-
nors, and the therapeutic dose range is needed to deter-
mine whether 2.5 mg is a suitable tablet strength for SLD
primaquine. Current SRA-approved primaquine tablets
also do not have “splitting lines” or “break lines” which
help facilitate pill-splitting for the administration of lower
doses. Even if these lines were added, however, the tablets
are already too small in size to split accurately; the 7.5 mg
Remedica tablet is only 6 mm in diameter.
Manufacturers expressed an interest in developing
lower strength primaquine tablets, but due to the com-
plexity of these processes, the exact tablet strength
needed to dose paediatric populations first needs to be
established. Usually, tablets are made smaller using thedosing schedule
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mix.” However, manufacturers stated that the prima-
quine tablets currently available are too small to be fur-
ther reduced. Since the ratio of API to excipients
determines the absorption and bioavailability of the API,
seeking regulatory approval for changes to this ratio usu-
ally requires the submission of bioequivalence study
data, which manufacturers expressed would both extend
the amount of time required for regulatory approval,
and furthermore add complexity to the process. It is
possible to expedite the regulatory approval process by
applying for a biowaiver, and although the properties of
primaquine are likely to fulfill these biowaiver require-
ments [14], manufacturers expressed a general lack of
understanding of this process. In the event that biowai-
ver requirements cannot be fulfilled, and furthermore
the absorption and bioavailability of the API for homo-
thetic mix(es) are not adequate for regulatory require-
ments, liquid-based formulations would need to be
developed to allow for the availability of lower strength
doses of primaquine.
Manufacturers also noted that small tablets are diffi-
cult to administer to paediatric patients, and dispersible
tablets or liquid formulations are usually preferred. How-
ever, they also stated that new formulations are expensive
and time consuming to develop, and may present add-
itional regulatory hurdles since bioequivalence data would
likely be required. Manufacturers also mentioned that it is
possible to crush currently available primaquine tablets for
paediatric use. At the time of study, the efficacy and repro-
ducibility of this method in clinical practice had not been
tested, but Sanofi has since released a Standard Operating
Procedure for this practice [15]. Manufacturers expressed
however, that the crushing of tablets is not an optimal so-
lution to paediatric dosing, as the primaquine API is ex-
tremely bitter and is frequently found not to be palatable.
Thus, they suggested that a child-friendly formulation
would be preferred, and should furthermore strive to mask
the bitter taste of primaquine API.
Country perspectives
African countries have little experience administering
primaquine as part of routine malaria case management,
and in-country interviews with key informants in Na-
tional Malaria Control Programmes and their partner or-
ganizations revealed varying levels of understanding
surrounding the use of primaquine. While some individ-
uals were unaware that SLD primaquine could be used to
clear mature P. falciparum gametocytes, others demon-
strated a detailed understanding of primaquine as a game-
tocytocide. Despite varying degrees of knowledge, all
countries in our case studies expressed interest in adopt-
ing primaquine as a transmission-blocking agent for
P. falciparum malaria.Respondents who were aware of primaquine and its
use as an anti-malarial drug cited several benefits. Pri-
marily, primaquine is an effective transmission-blocking
tool for the control and elimination of P. falciparum
malaria. In Ethiopia, the Ministry of Health (MoH)
noted that the use of primaquine could help to achieve
their ambitious goal of malaria elimination in low-trans-
mission areas by 2015. In Senegal, where malaria trans-
mission levels are higher and elimination is not the
primary objective, experts from the NMCP agreed on
the transmission-blocking potential of primaquine as a
critical tool for reducing malaria transmission. In Zanzibar,
health experts emphasized the need for primaquine to
eliminate P. falciparum malaria.
Safety
Despite interest in adopting primaquine as a P. falciparum
gametocytocide, all countries expressed safety concerns of
the haemolytic potential of primaquine in G6PDd individ-
uals. To facilitate the adoption of the WHO recommenda-
tion and to inform local deployment strategies, health
experts requested that maps of the local prevalence of
G6PD deficiency be made available. A second concern
noted by academics, drug regulators, international organi-
zations and national programmes arises from the potential
risks that primaquine may cause in vulnerable patient
groups, including small children and patients with other
co-morbidities including HIV, sickle cell anaemia or mal-
nutrition. Doctors and members of the NMCP in
Swaziland, a country with the highest HIV prevalence at
26.5% [16], voiced unease about the use of primaquine
among HIV-positive individuals because haematologic dis-
orders, including anaemia, are particularly common in
HIV-positive patients [17].
Regulatory issues
Countries explained a number of regulatory processes
that may introduce delays and pose challenges to the
adoption and implementation of SLD primaquine. Coun-
try anti-malarial drug guidelines are only reviewed, re-
vised, and updated on a periodic basis potentially
delaying anti-malarial policy changes at the national
level. However, countries suggested the possibility of
publishing a “circular” or interim recommendation,
which can act as a standing recommendation until new
guidelines are published. The process for policy change
also varies between countries. In Zambia, a pre-requisite
to drug registration is the inclusion of the product in
existing malaria treatment policy guidelines whereas in
Senegal, a drug is much more likely to be included in
their guidelines if it is already registered for in-country
use.
Regulatory requirements for primaquine registration
presented additional obstacles and delays to the adoption
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drug products can take anywhere from one month, which
is the case for Zanzibar, to up to two years, as is the case
for Ethiopia and Zambia. Fortunately, most countries have
an expedited review process, a process that generally takes
anywhere between three to six months. In Ethiopia and
Senegal, an expedited review is merited when the drug
under consideration has demonstrated a clear public
health need. In Zambia, an expedited review is possible if
the drug is registered in another Southern African Devel-
opment Community country. Swaziland does not cur-
rently have a drug regulatory authority, and generally
follows South Africa’s recommendations.
Some countries also have additional regulations that
pose further delays; in Senegal, manufacturers are re-
quired to submit product dossiers to make sure that
products are safe and effective for use by local patients.
Occasionally, in-country registration requires that the
product be deemed as cost-effective.Field deployment
Country programmes, international organizations and
researchers expressed differing opinions on the best
methods with which to deploy primaquine. They de-
scribed three dominant strategies for the use of prima-
quine to interrupt malaria transmission: the treatment of
confirmed clinical cases only, mass screen and treat
(MSaT) strategies, and mass drug administration (MDA)
campaigns. MSaT strategies aim to screen entire popula-
tions of interest, treating all individuals with detectable
levels of malaria parasitaemia. MDA entails the adminis-
tration of a curative regimen of anti-malarials to all indi-
viduals within a given locale, regardless of parasitaemia
or the presence of symptoms [18].
Among those interviewed, the most widely ac-
cepted SLD primaquine deployment option was the
treatment of confirmed clinical cases, noted by key
opinion leaders, researchers, local doctors, and mem-
bers of the NMCPs. However, there was interest in
broader deployment strategies for primaquine as its
use for clinical cases might have limited impact on
the overall parasite reservoir. Some international or-
ganizations, governmental agencies, and researchers
advocated for MSaT; in Ethiopia, the MoH recom-
mended the use of MSaT during regional epidemics
and MDA if the malaria slide positivity rate exceeds
50%. The NMCP in Swaziland was also open to tar-
geted MSaT with primaquine. At the time of study,
researchers in Zambia were considering the addition
of primaquine to an MSaT study using ACT. Malaria
researchers expressed a number of drawbacks to
MSaT however, including operational challenges and
high costs.Other malaria researchers believed that MDA could
best ensure malaria elimination within a population.
However, the notion of deploying primaquine in an
MDA campaign raised numerous concerns of safety in
individuals with G6PD deficiency. Experts raised ethical
questions about MDA, as to whether it is acceptable to
pose potential risks to individuals in order to benefit
entire populations. Furthermore, country programmes
were hesitant to implement a strategy that is not cur-
rently recommended by the WHO.
Discussion
Supply and demand are critical considerations for grow-
ing interest in the use of SLD primaquine to block P. fal-
ciparum transmission. This is the first study to identify
key barriers to the large-scale rollout of SLD primaquine
in sub-Saharan Africa, from which the following recom-
mendations for researchers, manufacturers, and malaria
programme managers can be derived.
Malaria programmes and manufacturers are in need of
a defined therapeutic dose range for SLD primaquine.
Not only will the therapeutic dose range inform the de-
velopment of new, lower strength primaquine tablets
and/or formulations by manufacturers; this dose range
will also guide therapeutic dosing regimens in the field,
and allay safety concerns of haemolytic effects in G6PDd
individuals, as the upper bound of the therapeutic dose
range is the highest safe dose in G6PDd individuals.
Manufacturers and malaria programmes agree on a need
for new, lower strength primaquine tablets to ensure ac-
curate dosing among paediatric subsections of the popula-
tion. After the therapeutic dose range of SLD primaquine
is established, manufacturers will gauge the level of invest-
ment to undertake for the development of a new prima-
quine product. A less expensive approach would be to
develop a new, lower strength primaquine tablet, including
the possibility of applying for a biowaiver. Larger invest-
ments would be needed to develop new formulation(s) of
primaquine, including a paediatric formulation that masks
the bitter taste of the primaquine API. As manufacturer
decisions are based on the profitability of the market and
level of investment required, the demand for new prima-
quine product(s), once available, should be periodically
forecasted, both to ensure that production levels are suffi-
cient, and to assess the size of the potentially growing
market for SLD primaquine products.
Defining the therapeutic dose range will likely be the
first step toward allaying safety concerns expressed by
malaria programme officers. Further data will be needed
to define the risk profile of SLD primaquine in vulner-
able populations, notably G6PDd individuals, small chil-
dren, those with malnutrition, anaemia, HIV, and/or
tuberculosis, with and without treatment for these co-
morbidities. The safety profile in these populations can
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through pharmacovigilance of programmes that are
already using primaquine as per the WHO recommen-
dation. Pharmacovigilance databases need to collect in-
formation on birth outcomes in women who take
primaquine before they are aware of their pregnancy, as
prescribing instructions warn against the use of prima-
quine in pregnancy and breastfeeding due to a lack of
data.
Malaria programme managers also expressed an inter-
est in G6PD prevalence maps, to better assess local
haemolytic risks in G6PDd populations. Currently avail-
able G6PD prevalence maps are based on variant pro-
portions or allele frequencies that have been derived
through population-level screening surveys, suggesting
that in Africa, G6PD deficiency is common, with a
prevalence of up to 32% in certain regions, mostly com-
prised of the mildly primaquine-sensitive A- variant of
G6PD deficiency [19]. Importantly, G6PD prevalence
maps are limited by the quality of screening methods
employed, and prevalence maps are unlikely to be useful
to malaria programme managers unless they achieve
very high resolutions [19]. It will be most important to
identify variants of G6PD deficiency that are highly sen-
sitive to the adverse effects of primaquine, and to then
consider the combination of frequency and severity.
While frequent mild variants may not be an issue, rare
severe variants might be problematic, and in areas where
severe variants are common, SLD primaquine should be
used with caution until its safety is established.
There are two methods to screen for G6PD activity
levels in order to establish prevalence maps, both of
which have important implications on their reliability.
The first method is to conduct genetic testing, which can
provide a clear diagnosis of a specific gene mutant, but is
limited by its inability to recognize unknown variants of
G6PD deficiency [20]. A second method, which is the
most widely used method, is to conduct biochemical,
phenotypic testing of G6PD enzyme activity to provide a
quantitative or qualitative readout, depending on the level
of infrastructure available [20]. However, phenotypic as-
says are limited by their ability to detect heterozygous fe-
males, as the G6PD gene is X-linked, and lyonization, or
partial inactivation of one female X chromosome, result
in wide variations in phenotypic G6PD activity that can
lead to the misclassification of G6PDd women as G6PD
normal. Biochemical approaches are also affected by the
duration of malaria infection, anaemia of the patient, and
other haematological parameters, further increasing the
chances of misclassifying a G6PDd person as G6PD nor-
mal. Importantly, both genetic and biochemical methods
require advanced laboratory infrastructure and skilled
technicians [21]. Recently, the BinaxNow® and CareStart®
point-of-care G6PD tests became available. While point-of-care tests do not require laboratory infrastructure, they
otherwise carry the same limitations posed by qualitative,
phenotypic testing. The generation of reliable, high-
resolution G6PD prevalence maps will be labor inten-
sive and costly, and is furthermore challenged by a lack
of consensus on the cut-off level of enzymatic activity
required to safeguard against severe haemolysis. There-
fore, the generation of prevalence maps must be
accompanied by clinical studies and/or pharmacovigi-
lance activities to ensure that the method of G6PD test-
ing employed, given its limitations, can sufficiently
denote the risks of severe haemolysis to in-country
programme managers.
The in-country procurement of primaquine also faces
numerous regulatory challenges, and suppliers need to
ensure that SLD primaquine products are either WHO
prequalified and/or SRA-approved. These regulatory re-
quirements will allow for the drug to be procured
through GFATM and other international donor funding
channels, and likely enable expedited in-country regis-
tration. Currently, no primaquine products have ob-
tained WHO prequalification, revealing a need for
primaquine tablets to be placed on the WHO prequalifi-
cation EOI list. As primaquine is recommended for use
in WHO treatment guidelines, this process is expected
to be straightforward [22]. The priority SLD primaquine
product that should be placed on the WHO EOI list for
prequalification will be the optimal tablet strength, based
on the therapeutic dose range, as soon as it is deter-
mined. This will enable for the SLD primaquine product
to be available to countries. In the meantime, it would
also be helpful for suppliers of non SRA-approved
primaquine products to place currently available tablet
strengths on the WHO prequalification EOI list. This
would increase the number of suppliers that can provide
primaquine through donor funding mechanisms, since
the Sanofi (15 mg) and Remedica (7.5 mg) products are
currently the only two available products that are pro-
curable through donor funding. If primaquine products
are placed on the WHO prequalification EOI list, manu-
facturers will be aware that a market exists, which can
encourage investments in the further development of
SLD primaquine products, as well as the regulatory ap-
provals needed.
While SRA approval and/or WHO prequalification are
often helpful for in-country registration, other regulatory
requirements vary at a country level. Countries consider-
ing the use of SLD primaquine should explore country
specific requirements ahead of time, in particular,
whether methods to expedite in-country registration are
available.
Finally, the optimal delivery strategy for SLD prima-
quine is at present unclear. Although the most widely
accepted use of primaquine is through the treatment of
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interest in the broader use of SLD primaquine through
MSaT or MDA campaigns. Recent studies in Burkina
Faso and Zanzibar have shown that MSaT using AL
alone did not reduce the incidence of P. falciparum mal-
aria in either location [23, 24]. It is unclear whether ef-
fectiveness could be improved through the addition of
SLD primaquine, or whether MSaT strategies themselves
are limited by the sensitivity of malaria RDTs [25]. In
any case, given the high cost of screening, MDA strat-
egies are likely to be much less costly than MSaT. To
date, there is no concrete evidence that the use of SLD
primaquine on a large-scale would impact P. falciparum
transmission in sub-Saharan Africa, largely due to chal-
lenges with measuring malaria transmission at a popula-
tion level. Mathematical malaria transmission models
offer a useful resource, suggesting that with high levels
of coverage, the addition of SLD primaquine to an arte-
misinin–piperaquine MDA deployment strategy provided
P. falciparum transmission-blocking effects, both acceler-
ating malaria elimination strategies and reducing the rate
of emergence of artemisinin-resistant malaria parasites
[26]. The use of primaquine through an MDA strategy is
indeed controversial, hinging on risk-benefit ratios and
safety, as primaquine is the only drug available to stop mal-
aria transmission from the human to the mosquito [7, 27].
Limitations
As this exercise focused on garnering an understanding
of the current manufacturing, regulatory and demand
landscape for SLD primaquine use, key manufacturers of
primaquine and a small group of purposefully selected
key informants from five African countries were chosen
for interviews. Inference is therefore limited and the re-
sults may not be generalizable to other contexts. Nonethe-
less, we attempted to conduct a diverse array of interviews
with representatives from industry and in-country key in-
formants, to capture the current perspectives surrounding
the production landscape for primaquine and in-country
perspectives on the use of primaquine as a P. falciparum
gametocytocide in sub-Saharan Africa.
Conclusion
Demand for SLD primaquine is growing rapidly, yet
multiple barriers to SLD primaquine rollout exist. Re-
search is needed to define the therapeutic dose range, to
develop a paediatric formulation, and to establish inter-
actions with co-morbidities and treatments for HIV/tu-
berculosis. Regulatory processes should be sought early;
countries should explore regulatory requirements ahead
of time, and there is an urgent need for suitable strength
primaquine tablets to obtain WHO prequalification. It is
critical to address these barriers to support the WHO
recommendation, particularly as programmes considerbroadening the use of SLD primaquine through MSaT
or MDA strategies.
Additional file
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and research experts implementing primaquine programmes.
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